ClinicalTrials.gg
Active, not recruitingNCT03997123CAPItello-290Updated Dec 22, 2025

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

A Phase 3 interventional study of Capivasertib and Paclitaxel in Triple Negative Breast Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 260 sites in 30 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
923
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca — 1 open to participants now, 6 under way, 1 of them phase 3. Triple Negative Breast Neoplasms · AstraZeneca.

Enrollment
Largest of 15
923 · median 99
Started
2019
with 1 other
Phase 3
Only one
of the 15
Registered
11th of 15
by date

Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, this one has the largest enrollment, is one of 2 that started in 2019, is the only one in phase 3, and was the 11th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

1 of the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Read the detailed description

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer (TNBC)

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • Breast Cancer;
  • Triple-negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed TNBC from most recently collected tumour tissue sample
  2. or locally recurrent disease; locally recurrent disease most not be amenable to resection with curative intent (patient who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible)
  3. PS: 0-1
  4. according to 1.1 and/or lytics or mixedbone lesions that can be assessed by CT or MRI in the absence of measurable disease
  5. FFPE tumour sample from primary/recurrent cancer

Exclusion criteria

Exclusion Criteria:

  1. Prior Chemotherapy in the or adjuvant setting within 6 months from the end of chemotherapy to the date of randomization; taxane chemotherapy in the neoadjuvant or adjuvant setting within 12 months from the end of chemotherapy to the start of randomization
  2. Prior systematic therapy for inoperable locally advanced or disease
  3. Prior treatment with any of the treatments listed below. Patients are not eligible to enter the study if they have received any of the medications specified below or are unable to meet the cautions and restrictions:

    • AKT, PI3K, and/or mTOR inhibitors
    • Capivasertib in the present study (ie, any dosing with capivasertib due to previous participation in this study)
    • Any other chemotherapy, immunotherapy, medication (other than ) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long halflife (eg, biologics) as agreed by the sponsor
    • Potent inhibitors or inducers of within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to the first dose of study treatment.
  4. Radiotherapy with a wide field of radiation within 4 weeks before the first dose of study treatment (capivasertib/placebo)
  5. Pre-existing sensory or motor polyneuropathy ≥grade 2 according to v5
  6. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment
  7. Any of the following cardiac criteria at screening:

    • Mean resting interval (QTc) >470 msec obtained from 3 consecutive ECGs
    • Any abnormalities in rhythm, conduction or morphology of resting (eg, complete left bundle branch block, third degree heart block)
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for Torsades de Pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
    • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure (NYHA) grade ≥2
    • Uncontrolled hypotension - SBP \<90 mmHg and/or DBP \<50 mmHg
    • Cardiac outside institutional range of normal or \<50% (whichever is higher) as measured by echocardiogram (or multiplegated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive).
  8. Clinically significant abnormalities of glucose metabolism as defined by any of the following at screening:

    • Patients with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment
    • ≥8.0% (63.9 mmol/mol)
  9. Inadequate bone marrow reserve or organ function at screening
  10. Currently pregnant (confirmed with positive pregnancy test) or breast-feeding
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
923 participants (actual)

Study arms

  • Experimental
    Capivasertib + Paclitaxel

    Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle.

    Drug: Capivasertib · Drug: Paclitaxel

  • Placebo comparator
    Placebo + Paclitaxel

    Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle.

    Drug: Paclitaxel · Drug: Placebo

Interventions

  • 400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.

    Also known as: AZD5363

  • 80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.

  • DrugPlacebo

    Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle

    Also known as: Placebo tablets to match capivasertib

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS)

    Time frame: The time from date of randomisation to the date of death due to any cause up to approximately 42 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival by investigator assessment (in accordance with RECIST 1.1)

    Time frame: The time from date of randomization to the date of progression or death due to any cause, whichever occurs earlier, up to approximately 42 months

  2. Investigator assessment of PFS2

    PFS2 - time from randomisation to second progression or death

    Time frame: Time from randomization to second progression or death due to any cause up to approximately 42 months

  3. Response Rate (ORR)

    Response Rate (ORR) - percentage of patients with at least one investigator-assessed visit response of complete or partial response (as assessed by the investigator, using RECIST 1.1)

    Time frame: Up to approximately 42 months

  4. Safety and tolerability of drugs by assessment of AEs/SAEs

    Graded according to the National Cancer Institute (NCI CTCAE)

    Time frame: Up to approximately 42 months

  5. Minimum plasma concentration(Cmin), plasma concentration1-2 hours post-dose (C1-2h) and 4 hours post-dose (C4h) during months 1 and 2

    Plasma PK parameters derived from a population model as data permits

    Time frame: During months 1 and 2

  6. EORTC QLQ BR23(European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire breast cancer specific module)

    The self-administered instrument includes 23-items and yields 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Items are scored on a 4-point verbal rating scale: "Not at All," "A Little," "Quite a Bit," and "Very Much". Scores are transformed to a 0 to 100 scale, where higher scores indicate better unctioning, better HRQoL, or greater level of symptom.

    Time frame: approximately up to 42 months

  7. The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items)

    5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), and global health status/QoL scale, along with 5 individual item symptom scores (appetite loss, dyspnoea, insomnia, constipation, and diarrhoea. The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001). Higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales/scores represent greater symptom severity.

    Time frame: approximately up to 42 months

  8. Duration of Response (DoR)

    Duration of Response (DoR) - time from the date of first documented response until date of documented progression (as assessed by the investigator, using RECIST 1.1) or death in the absence of disease progression.

    Time frame: Up to approximately 42 months

  9. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) - number of patients with complete or partial response or with stable disease maintained ≥24 weeks (as assessed by the investigator, using RECIST 1.1) divided by the number of patients in the analysis

    Time frame: Up to approximately 42 months

07

Study locations

260 sites
  • Research Site
    Whittier, California 90602, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Nyack, New York 10960, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Harrisburg, Pennsylvania 17109, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78758, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Buenos Aires, C1125ABD, Argentina
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    CABA, C1019ABS, Argentina
  • Research Site
    CABA, C1426ANZ, Argentina
  • Research Site
    Ciudad Autonomade Buenos Aires, 1426, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Goiânia, 74605-070, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01317-000, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changsha, 410078, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanyang, 473009, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Floridablanca, 681004, Colombia
  • Research Site
    Ibague, 730006, Colombia
  • Research Site
    Medellín, 5001000, Colombia
  • Research Site
    Montería, 23001, Colombia
  • Research Site
    Valledupar, 200001, Colombia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Prague, 100 34, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Brest, 29609, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13009, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Nice, 6189, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Saint-Herblain, 44805, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Athens, 115 22, Greece
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Budapest, 1062, Hungary

Showing the first 100 of 260 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Mar 2026, 80 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 80 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2019
First posted
Jun 25, 2019
StartActual
Jun 25, 2019
Primary completionEst.
Mar 16, 2026
CompletionEst.
Mar 16, 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03997123
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Jun 25, 2019
Primary completion
Mar 16, 2026 (estimated)
Completion
Mar 16, 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Peter Schmid, MD,PhD,FRCP
principal investigator · Centre for Experimental Cancer Medicine (CECM), Barts Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion